SPOTLIGHT -
While relatively uncommon in this age group, diagnostic, therapeutic differences do occur
Aurion Biotech doses first Canadian patient in Phase 1/2 ABA-1, CLARA clinical trial of AURN001
EyePod: Modifier Gene Therapy: What is it?
Navigating ocular effects of cancer therapy: Insights from breast cancer and head-neck cancers
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
ABVC BioPharma reaches global licensing deal for ophthalmology pipeline
Plastic surgery: When specialties overlap